Phase I Study of the Combination of MLN9708 and Fulvestrant (Millennium)
Phase I Study of the Combination of MLN9708 and Fulvestrant in Patients With Advanced Estrogen Receptor Positive Breast Cancer
Sponsor: Dartmouth-Hitchcock Medical Center
Terminated
Low accrual
Other terminated trials from Dartmouth-Hitchcock Medical Center
- Anaplastic Astrocytoma · Aug 2025
- Lumbar Puncture · Phase NA · Dec 2023
- Vaccine Hesitancy · Phase NA · Jul 2023
- Pituitary Macroadenoma · Phase NA · Jul 2023
- Depression, Bipolar · Phase NA · Sep 2022
See all terminations from Dartmouth-Hitchcock Medical Center
Other Breast Cancer trials with similar outcome
A PHASE1 clinical study on Breast Cancer, this trial is terminated or withdrawn. The trial is conducted by Dartmouth-Hitchcock Medical Center and has accumulated 8 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
May 2019 — Jan 2021 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Oct 2018 — May 2019 [monthly]
Recruiting PHASE1
▶ Show 3 earlier versions
-
Jun 2018 — Oct 2018 [monthly]
Recruiting PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Jun 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Dartmouth-Hitchcock Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .